MK-0354 Uses, Dosage, Side Effects and more
MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.
| Attribute | Details |
|---|---|
| Trade Name | MK-0354 |
| Generic | MK-0354 |
| Type | |
| Formula | C7H8N6 |
| Weight | Average: 176.183 Monoisotopic: 176.081044282 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in atherosclerosis.
